Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study
Company Announcement Preliminary data shows responses achieved in 11 of 34 evaluable patients with cervical cancer treated with tisotumab vedotin Next steps in clinical development of tisotumab vedotin in this indication under active consideration …